"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.

“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia ...

"The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent within a year at [baseline]," says ...

Two-thirds of patients with a complete response at three months avoided cystectomy at 60 months. Among cystectomy patients, only six progressed to muscle-invasive bladder cancer, indicating low ...

Belzutifan, a HIF-2α inhibitor, is approved for von Hippel-Lindau disease and advanced renal cell carcinoma, with a focus on its safety profile. The study found 28% of patients experienced grade 3 ...

Nadofaragene firadenovec offers a 66% probability of cystectomy-free survival at 60 months for BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The phase 3 study enrolled 107 patients, with 103 ...

The NanoKnife System received FDA 510(k) clearance for prostate tissue ablation, utilizing irreversible electroporation technology to target tumors while preserving critical functions. The PRESERVE ...

Delayed diagnosis or treatment was the primary cause of malpractice lawsuits in testicular cancer cases, accounting for 87.5% of claims. No malpractice claims were associated with surveillance ...

TAR-200 is an intravesical gemcitabine-releasing system for BCG-unresponsive NMIBC, evaluated in the SunRISe-1 trial. The trial's focus was on TAR-200 monotherapy, with other cohorts including ...

"Most of the AEs were grade 1 and 2. These consisted of frequency, urgency, UTIs—again, things we're very used to with intravesical therapies," says Siamak Daneshmand, MD.

Focal ablation for radiorecurrent localized prostate cancer shows favorable functional outcomes compared to salvage radical prostatectomy. Current studies on salvage focal ablation are limited, but ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...